Compare Neurocrine Biosciences Inc (NBIX) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Open Text Corporation — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Open Text Corporation trades at $23.7 (market cap $5.61B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.6× Open Text Corporation's market cap, and Open Text Corporation pays a 4.82% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Open Text Corporation for 23 Days on average.
| NBIX | OTEX | |
|---|---|---|
Market Cap | $14.36B | $5.61B |
Volume | 1,237,180 | 1,197,475 |
Sector | Health | Technology |
52-Week High | $185.50 | $39.69 |
52-Week Low | $123.10 | $20.01 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $14.37B | $10.63B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
OpenText (OTEX) trades at $23.24, up 0.43% with a bearish technical signal despite strong fundamentals. The company shows robust profitability with 73.74% gross margins and consistent earnings beats, while actively managing debt through recent $1 billion notes offering. Valuation appears attractive with P/E of 9.01 and P/S of 1.1, trading below analyst consensus target of $28.30.
The stock presents value opportunity with discounted multiples and improving cloud momentum, though technical weakness and debt refinancing activities warrant caution. Upside potential exists if earnings growth continues, while execution risks and market sentiment remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
